{"a":[{"_":"Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector","$":{"href":"/pharma/sanofi-gains-fda-thumbs-sarclisa-1st-cancer-drug-be-delivered-body-injector","hreflang":"en"}}]}
RegulatoryapprovedSarclisaDarzalexPositive
AI Analysis
Summary
Sanofi gained FDA approval for a subcutaneous formulation of Sarclisa with on-body injector delivery for multiple myeloma, marking the first cancer drug delivered via this method and intensifying competition with Johnson & Johnson's Darzalex.
Outcome Details
FDA approval of subcutaneous formulation of Sarclisa delivered manually or by on-body injector
Importance:8/10
Sentiment:
0.85
FDA approvaloncologydrug formulationmultiple myelomasubcutaneous injectionmedical devicecompetitive advantage
Related Companies
Read the original article
Published by FiercePharma on July 10, 2026 8:39 AM